These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 26732082)

  • 1. Response of symptomatic brain metastases from HER-2 overexpressing breast cancer with T-DM1.
    de Vries CL; Linn SC; Brandsma D
    J Neurooncol; 2016 Apr; 127(2):401-3. PubMed ID: 26732082
    [No Abstract]   [Full Text] [Related]  

  • 2. [Trastuzumab emtansine in the systemic treatment of HER-2-positive breast cancer brain metastases].
    Frenel JS; Bally O; Bourbouloux E; Berton-Rigaud D; Campone M; Bachelot T; Heudel PÉ
    Bull Cancer; 2016 May; 103(5):507-10. PubMed ID: 26992855
    [No Abstract]   [Full Text] [Related]  

  • 3. Breast cancer brain metastases responding to primary systemic therapy with T-DM1.
    Bartsch R; Berghoff AS; Preusser M
    J Neurooncol; 2014 Jan; 116(1):205-6. PubMed ID: 24065570
    [No Abstract]   [Full Text] [Related]  

  • 4. Activity of T-DM1 in Her2-positive breast cancer brain metastases.
    Bartsch R; Berghoff AS; Vogl U; Rudas M; Bergen E; Dubsky P; Dieckmann K; Pinker K; Bago-Horvath Z; Galid A; Oehler L; Zielinski CC; Gnant M; Steger GG; Preusser M
    Clin Exp Metastasis; 2015 Oct; 32(7):729-37. PubMed ID: 26303828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Caveolin-1 Dependent Endocytosis Enhances the Chemosensitivity of HER-2 Positive Breast Cancer Cells to Trastuzumab Emtansine (T-DM1).
    Chung YC; Kuo JF; Wei WC; Chang KJ; Chao WT
    PLoS One; 2015; 10(7):e0133072. PubMed ID: 26172389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of T-DM1 in HER-2 positive central nervous system breast cancer metastases.
    Torres S; Maralani P; Verma S
    BMJ Case Rep; 2014 Aug; 2014():. PubMed ID: 25123575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preliminary results of the concurrent use of radiotherapy for bone metastases and trastuzumab emtansine in patients with HER2-positive metastatic breast cancer.
    Géraud A; Xu HP; Beuzeboc P; Kirova YM
    Cancer Radiother; 2016 Jun; 20(4):312-3. PubMed ID: 27342941
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature.
    Martínez MT; Pérez-Fidalgo JA; Martín-Martorell P; Cejalvo JM; Pons V; Bermejo B; Martín M; Albanell J; Lluch A
    Crit Rev Oncol Hematol; 2016 Jan; 97():96-106. PubMed ID: 26318092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Metastatic Breast Cancer Previously Treated With Chemotherapy and 2 or More HER2-Targeted Agents: Results From the T-PAS Expanded Access Study.
    Yardley DA; Krop IE; LoRusso PM; Mayer M; Barnett B; Yoo B; Perez EA
    Cancer J; 2015; 21(5):357-64. PubMed ID: 26389758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trastuzumab emtansine for advanced HER2-positive breast cancer and beyond: genome landscape-based targets.
    Cho WC; Roukos DH
    Expert Rev Anticancer Ther; 2013 Jan; 13(1):5-8. PubMed ID: 23259420
    [No Abstract]   [Full Text] [Related]  

  • 11. T-DM1 Extends Survival in HER2+ Breast Cancer.
    Cancer Discov; 2016 Feb; 6(2):OF4. PubMed ID: 26676162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [T-DM1 and pertuzumab: emerging anti-HER2 therapeutics].
    Noguchi E; Shimizu C
    Gan To Kagaku Ryoho; 2013 Jan; 40(1):10-4. PubMed ID: 23306913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer.
    Krop I; Winer EP
    Clin Cancer Res; 2014 Jan; 20(1):15-20. PubMed ID: 24135146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T-DM1 as a New Treatment Option for Patients with Metastatic HER2-positive Breast Cancer in Clinical Practice.
    Michel LL; Bermejo JL; Gondos A; Marmé F; Schneeweiss A
    Anticancer Res; 2015 Sep; 35(9):5085-90. PubMed ID: 26254411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: an integrated safety analysis.
    Diéras V; Harbeck N; Budd GT; Greenson JK; Guardino AE; Samant M; Chernyukhin N; Smitt MC; Krop IE
    J Clin Oncol; 2014 Sep; 32(25):2750-7. PubMed ID: 25024070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exposure-response relationship of T-DM1: insight into dose optimization for patients with HER2-positive metastatic breast cancer.
    Wang J; Song P; Schrieber S; Liu Q; Xu Q; Blumenthal G; Amiri Kordestani L; Cortazar P; Ibrahim A; Justice R; Wang Y; Tang S; Booth B; Mehrotra N; Rahman A
    Clin Pharmacol Ther; 2014 May; 95(5):558-64. PubMed ID: 24488143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ado-trastuzumab emtansine (Kadcyla) for HER2-positive metastatic breast cancer.
    Med Lett Drugs Ther; 2013 Sep; 55(1425):75-6. PubMed ID: 24662957
    [No Abstract]   [Full Text] [Related]  

  • 18. HER2-positive breast cancer: a new piece of the puzzle.
    Gnant M; Bartsch R; Steger GG
    Lancet Oncol; 2014 Jun; 15(7):668-9. PubMed ID: 24793817
    [No Abstract]   [Full Text] [Related]  

  • 19. Trastuzumab-DM1: building a chemotherapy-free road in the treatment of human epidermal growth factor receptor 2-positive breast cancer.
    Isakoff SJ; Baselga J
    J Clin Oncol; 2011 Feb; 29(4):351-4. PubMed ID: 21172881
    [No Abstract]   [Full Text] [Related]  

  • 20. T-DM1 aids patients with advanced breast cancer.
    Cancer Discov; 2013 Dec; 3(12):OF5. PubMed ID: 24327714
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.